首页 文献索引 SCI期刊 AI助手
条件筛选
相关性 最新发表 最早发表
全文 标题 期刊 作者
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
模糊 精准
{{tag.shortname||tag.name}}:{{getFilterLabel(field)}} Clear All
Savrina Manhas,Joseph P Brooker,Cory Shetler et al. Savrina Manhas et al.
Despite adherence to antiretroviral therapy (ART), low levels of plasma virus persist in most individuals with HIV-1. In a small subset of these individuals, this non-suppressible viremia is detected by routine clinical testing (plasma HIV-...
Paula Cohen,Bronwen E Lambson,Nonhlanhla N Mkhize et al. Paula Cohen et al.
The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against neutralization-sensitive...
Supratik Das,Hilal Ahmad Parray,Adarsh Kumar Chiranjivi et al. Supratik Das et al.
Efficiently cleaved HIV-1 Envs are the closest mimics of functional Envs as they specifically expose only bNAb (broadly neutralizing antibody) epitopes and not non-neutralizing ones, making them suitable for developing vaccine immunogens. W...
Carolina Beltran-Pavez,Ilja Bontjer,Nuria Gonzalez et al. Carolina Beltran-Pavez et al.
Longitudinal studies in HIV-1-infected individuals have indicated that 2 to 3 years of infection are required to develop broadly neutralizing antibodies. However, we have previously identified individuals with broadly neutralizing activity ...
Yuta Hikichi,Rachel Van Duyne,Phuong Pham et al. Yuta Hikichi et al.
Despite the effectiveness of antiretroviral (ARV) therapy, virological failure can occur in some HIV-1-infected patients in the absence of mutations in drug target genes. We previously reported that, in vitro, the lab-adapted HIV-1 NL4-3 st...
Supratik Das,Rajesh Kumar,Shubbir Ahmed et al. Supratik Das et al.
The enormous diversity of HIV-1 is a significant impediment in selecting envelopes (Envs) that can be suitable for designing vaccine immunogens. While tremendous progress has been made in developing soluble, trimeric, native-like Env protei...
Sean P O&#x;Brien,Adrienne E Swanstrom,Amarendra Pegu et al. Sean P O&#x;Brien et al.
Chimeric Simian-Human Immunodeficiency Viruses (SHIVs) are an important tool for evaluating anti-HIV Env interventions in nonhuman primate (NHP) models. However, most unadapted SHIVs do not replicate well in vivo limiting their utility. Fur...
Sweety Samal,Supratik Das,Saikat Boliar et al. Sweety Samal et al.
Background: HIV-1 Env gp160 is cleaved to form gp120 and gp41 and the functional HIV-1 Env is a trimer of non-covalently associated heterodimeric subunits, gp120 and gp41. The cleaved, native, trimeric form of Envs expose...
Mohammed Asmal,Corinne Luedemann,Christy L Lavine et al. Mohammed Asmal et al.
Simian-human immunodeficiency viruses (SHIVs) that mirror natural transmitted/founder (T/F) viruses in man are needed for evaluation of HIV-1 vaccine candidates in nonhuman primates. Currently available SHIVs contain HIV-1 env genes from ch...
耗时 0.12316 秒,为您在 48229835 条记录里面共找到 26 篇文章 [XML]